QR Pharma
259 Radnor Chester Road
Suite 205
Radnor
Pennsylvania
19087
United States
Tel: 484-253-2296
Fax: 484-253-2288
Website: http://www.qrpharma.com/
Email: info@QRPharma.com
26 articles about QR Pharma
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
QR Pharma Presents New Data On Posiphen In Down Syndrome At The Alzheimer's Disease International Conference (AAIC 2017 London)
7/12/2017
-
QR Pharma Presents New Data On Posiphen In Alzheimer's And Parkinson's Disease At The 13th AD/PD International Conference
3/16/2017
-
QR Pharma Release: Company Announces New Scientific Advisory Board
1/24/2017
-
QR Pharma Raises $800,000 Of Series A Preferred Stock
10/27/2016
-
QR Pharma Issues $5.7 Million Of Series A Preferred Stock
5/26/2015
-
Peter Davies, The 2015 Recipient Of The Potamkin Award, Joins The Scientific Advisory Board Of QR Pharma
4/29/2015
-
QR Pharma Begins Collaboration On Posiphen And Huntington’s Disease
2/4/2015
-
QR Pharma Announces The Appointment Of New Chairman And New Board Member
1/6/2015
-
QR Pharma and University of California, Los Angeles (UCLA) Awarded $3 Million US Army Grant to Test Posiphen in Rat Models of Concussion and Blunt Head Trauma
10/10/2013
-
QR Pharma Release: Posiphen Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice
10/22/2012
-
QR Pharma Announces the Start of a Phase I Clinical Study for Bisnorcymserine
7/24/2012
-
QR Pharma Awarded Funding by The Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease
3/6/2012
-
QR Pharma Reports Results from SBIR Grant by NIA/National Institutes of Health (NIH) to Study Posiphen(R) and Metabolites in Various Models
10/13/2011
-
Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma’s Medical Advisory Board
2/3/2011
-
QR Pharma to Present at the 44th Winter Conference on Brain Research
1/19/2011
-
QR Pharma Receives FDA Clearance to Conduct Clinical Trials with Its Second Novel Alzheimer Compound, Bisnorcymserine
12/2/2010
-
QR Pharma Awarded SBIR Grant by National Institute on Aging/National Institutes of Health (NIH) to Test Posiphen(R) and Metabolites in Various Models
9/21/2010
-
QR Pharma’s Posiphen Was Shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein
7/14/2010
-
Beacon Enterprise Solutions Announces Additional Contract with Fortune 100 Pharmaceutical Company
7/14/2010